Macarulla Teresa, Casado Esther, Ramos Francisco Javier, Valverde Claudia, Tabernero Josep
Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Onkologie. 2006 Mar;29(3):99-105. doi: 10.1159/000091013. Epub 2006 Mar 3.
Gastrointestinal (GI) cancer continues to be a leading cause of cancer morbidity and mortality worldwide. Over the past decade the treatment options for patients with GI cancers have increased with the advent of newer combination chemotherapy regimes. Despite these clinical advances, new strategies are warranted in order to improve the efficacy as well as the safety. New molecular targets have provided novel opportunities in the treatment of GI cancer. One of the most advanced new approaches to date is the use of targeted inhibitors of the epidermal growth factor receptor (EGFR). In this review we describe the current status of therapeutic strategies based on EGFR inhibitors in the treatment of GI cancer.
胃肠道（GI）癌仍然是全球癌症发病和死亡的主要原因。在过去十年中，随着更新的联合化疗方案的出现，胃肠道癌患者的治疗选择有所增加。尽管有这些临床进展，但仍需要新的策略来提高疗效和安全性。新的分子靶点为胃肠道癌的治疗提供了新的机会。迄今为止，最先进的新方法之一是使用表皮生长因子受体（EGFR）的靶向抑制剂。在这篇综述中，我们描述了基于EGFR抑制剂的治疗策略在胃肠道癌治疗中的现状。
